Scholarlink

Background <p>Many studies have indicated that epigenetic mechanisms, particularly DNA methylation, play an important role in regulating genes involved in glucose and lipid metabolism, oxidative stress, and energy homeostasis. Among these, <i>TXNIP</i> and <i>ADRB3</i> are key metabolic regulators linked to insulin signaling, adipose tissue function, and energy expenditure. This study aimed to evaluate promoter methylation levels of <i>TXNIP</i> and <i>ADRB3</i> in individuals with metabolic syndrome compared with healthy controls and to investigate their associations with clinical and biochemical parameters.</p> Methods <p>A total of 95 patients with metabolic syndrome and 95 age- and sex-matched healthy controls were enrolled. Genomic DNA was extracted from whole blood, and promoter methylation levels of <i>TXNIP</i> and <i>ADRB3</i> were quantified using the MethyQESD method followed by quantitative real-time PCR.</p> Results <p><i>TXNIP</i> promoter methylation was significantly lower in patients compared with controls (19.59 ± 17.42 vs. 38.77 ± 17.57, <i>P</i> &lt; 0.001), whereas no significant difference was observed for <i>ADRB3</i> methylation (<i>P</i> &gt; 0.05). <i>TXNIP</i> showed good diagnostic performance for metabolic syndrome (AUC = 0.837, <i>P</i> &lt; 0.001). In patients, <i>TXNIP</i> methylation decreased progressively with increasing FBS, while <i>ADRB3</i> methylation showed an opposite trend (<i>P</i> &lt; 0.001 for both). <i>TXNIP</i> methylation was positively correlated with HDL-C, whereas <i>ADRB3</i> methylation showed negative correlation with HDL-C and a positive correlation with BMI and waist circumference.</p> Conclusions <p>Promoter methylation of <i>TXNIP</i> and <i>ADRB3</i> was associated with metabolic syndrome-related traits. <i>TXNIP</i> hypomethylation showed strong diagnostic potential, while <i>ADRB3</i> methylation was shown to be linked to disease-related metabolic parameters, indicating a role in disease severity rather than classification.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Promoter methylation of TXNIP and ADRB3 genes: potential blood-based biomarkers for metabolic syndrome

  • 期刊论文

  • 发表日期：

    2026年6月19日

查看全文
  • Saeed Esmaeili Dizghandi,
  • Sahar Mostafapour,
  • Fatemeh Khodabandehloo,
  • Behrang Alani,
  • Leila Saremi,
  • Taiebe Kenarangi,
  • Meysam Mosallaei,
  • Boshra Rezvankhah

摘要

Background

Many studies have indicated that epigenetic mechanisms, particularly DNA methylation, play an important role in regulating genes involved in glucose and lipid metabolism, oxidative stress, and energy homeostasis. Among these, TXNIP and ADRB3 are key metabolic regulators linked to insulin signaling, adipose tissue function, and energy expenditure. This study aimed to evaluate promoter methylation levels of TXNIP and ADRB3 in individuals with metabolic syndrome compared with healthy controls and to investigate their associations with clinical and biochemical parameters.

Methods

A total of 95 patients with metabolic syndrome and 95 age- and sex-matched healthy controls were enrolled. Genomic DNA was extracted from whole blood, and promoter methylation levels of TXNIP and ADRB3 were quantified using the MethyQESD method followed by quantitative real-time PCR.

Results

TXNIP promoter methylation was significantly lower in patients compared with controls (19.59 ± 17.42 vs. 38.77 ± 17.57, P < 0.001), whereas no significant difference was observed for ADRB3 methylation (P > 0.05). TXNIP showed good diagnostic performance for metabolic syndrome (AUC = 0.837, P < 0.001). In patients, TXNIP methylation decreased progressively with increasing FBS, while ADRB3 methylation showed an opposite trend (P < 0.001 for both). TXNIP methylation was positively correlated with HDL-C, whereas ADRB3 methylation showed negative correlation with HDL-C and a positive correlation with BMI and waist circumference.

Conclusions

Promoter methylation of TXNIP and ADRB3 was associated with metabolic syndrome-related traits. TXNIP hypomethylation showed strong diagnostic potential, while ADRB3 methylation was shown to be linked to disease-related metabolic parameters, indicating a role in disease severity rather than classification.